-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;line-height:1.
According to our statistics, in the 2020 Global Pharmaceutical Top50, Japanese pharmaceutical companies account for 7 companies, ranking relatively high, of which Takeda ranks 10; China has 4 companies on the list, ranking relatively low, but the gap is gradually narrowing.
Only by driving innovation through R&D can innovation gain competitiveness beyond its peers.
For this reason, let's compare the R&D investment of Chinese and Japanese pharmaceutical companies.
544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;line-height:2em;">
Selecting all pharmaceutical companies listed in the two places, the R&D expenditure ranking of the top 10 in the first three quarters of 2020 is shown in the following chart, of which BeiGene has invested 6.
068 billion yuan in R&D, ranking first.
Hengrui Pharmaceutical's R&D investment of 3.
344 billion yuan ranked second, and CSPC's R&D investment of 2.
266 billion yuan ranked third.
The top 10 pharmaceutical companies invested a total of about 20.
35 billion yuan in R&D expenses in the first three quarters, with an average R&D investment of about 2.
03 billion yuan.
(In addition, in the Hong Kong stocks, CStone Pharmaceuticals, China Resources Pharmaceuticals, Hansen Pharmaceuticals, Simcere Pharmaceuticals and Fuhong Henlius have invested in R&D of RMB 300-500 million in the interim report, but the third quarter report was not disclosed, so the ranking was not made)Let's take A-share and Hong Kong-listed companies as examples.
Selecting all pharmaceutical companies listed in the two places, the R&D expenditure ranking of the top 10 in the first three quarters of 2020 is shown in the following chart, of which BeiGene has invested 6.
068 billion yuan in R&D, ranking first.
Hengrui Pharmaceutical's R&D investment of 3.
344 billion yuan ranked second, and CSPC's R&D investment of 2.
266 billion yuan ranked third.
The top 10 pharmaceutical companies invested a total of about 20.
35 billion yuan in R&D expenses in the first three quarters, with an average R&D investment of about 2.
03 billion yuan.
(Also the cornerstone of medicine in Hong Kong, China Resources medicine, pharmacy Hansen, Simcere and complex macros Hanlin and other R & D investment in the mid-year report 3-5 billion, but did not disclose the three quarterly, it did not rank) us to A Take the listed companies of Hong Kong stocks and Hong Kong stocks as examples.
Selecting all pharmaceutical companies listed in the two places, the R&D expenditure ranking of the top 10 in the first three quarters of 2020 is shown in the following chart, of which BeiGene has invested 6.
068 billion yuan in R&D, ranking first.
544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;line-height:2em;">
According to our ranking of the Top10 R&D investment in the first three quarters of the fiscal year, Takeda ranked first, with R&D investment of 3.
254 billion US dollars, which is approximately 21.
02 billion yuan (based on 1 US dollar = 6.
46 yuan).
As shown in the top 10 ranking of Japanese pharmaceutical companies' R&D investment:The Japanese fiscal year runs from April 1, 2020 to March 31, 2021.
According to our ranking of the Top10 R&D investment in the first three quarters of the fiscal year, Takeda ranked first, with R&D investment of 3.
254 billion US dollars, which is approximately 21.
02 billion yuan (based on 1 US dollar = 6.
46 yuan).
As shown in the top 10 ranking of Japanese pharmaceutical companies' R&D investment:
629 billion in research and development in the first three quarters, or about RMB 75.
12 billion.
The average R&D investment of each pharmaceutical company is about 7.
5 billion yuan.
(Among them: Chugai Pharmaceutical is a subsidiary of Roche Holdings)Japan's top 10 pharmaceutical companies spent a total of US$11.
629 billion in research and development in the first three quarters, or about RMB 75.
12 billion.
The average R&D investment of each pharmaceutical company is about 7.
5 billion yuan.
(Among them: Chugai Pharmaceutical is a subsidiary of Roche Holdings)
544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;line-height:2em;">
Top10 total R & D investment from the point of view, the first three quarters of Japan's total investment of about 75.
12 billion yuan, the average invested 7.
5 billion yuan; Chinese pharmaceutical companies listed Top10 first three quarters of total R & D expenses 203.
5 or so billion, the average R & D investment in 20 one hundred million yuan about.
The R&D investment of Chinese pharmaceutical companies is equivalent to about a quarter of that of Japanese pharmaceutical companies.
The R&D investment of Japan's top 10 pharmaceutical companies accounts for about 17% of revenue , and most of the R&D investment accounts for more than 15% of revenue .
Most of the R&D investment of Chinese pharmaceutical companies accounts for less than 10% of revenue .
From the foregoing, we can clearly see that there is a large gap in R&D investment between Chinese and Japanese listed pharmaceutical companies.
Top10 total R & D investment from the point of view, the first three quarters of Japan's total investment of about 75.
12 billion yuan, the average invested 7.
5 billion yuan; Chinese pharmaceutical companies listed Top10 first three quarters of total R & D expenses 203.
5 or so billion, the average R & D investment in 20 one hundred million yuan about.
The R&D investment of Chinese pharmaceutical companies is equivalent to about a quarter of that of Japanese pharmaceutical companies.
The R&D investment of Japan's top 10 pharmaceutical companies accounts for about 17% of revenue , and most of the R&D investment accounts for more than 15% of revenue .
Most of the R&D investment of Chinese pharmaceutical companies accounts for less than 10% of revenue .
The top 10 listed pharmaceutical companies in China spent about 20.
35 billion yuan in research and development in the first three quarters , with an average research and development investment of about 2 billion yuan.
The R&D investment of Chinese pharmaceutical companies is equivalent to about a quarter of that of Japanese pharmaceutical companies.
The R&D investment of Japan's top 10 pharmaceutical companies accounts for about 17% of revenue , and most of the R&D investment accounts for more than 15% of revenue .
Most of the R&D investment of Chinese pharmaceutical companies accounts for less than 10% of revenue .
Hengrui Medicine’s revenue in the first three quarters of 2020 was 19.
4 billion yuan, an increase of 14.
56%, and its net profit was 4.
25 billion yuan, an increase of 14%; Takeda’s revenue in the first three quarters of 2020 was US$23 billion, a decrease of 3.
6%, and its net profit was US$1.
Comparing Hengrui Medicine, the benchmark of China's innovative drugs, with Takeda in Japan, Hengrui Medicine’s R&D investment as a percentage of revenue increased from 10% in 2015 to 17% in 2019, and the gap with Takeda is narrowing.
Hengrui is also accelerating its deployment in recent years.
544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;line-height:2em;">
In recent years, with the strong support of national policies and social capital, Chinese pharmaceutical companies have developed Chinese-style Big Pharma, Biopharma and Biotech companies, and have now emerged in the field of global innovation.
For details, please refer to: weixin.
qq.
com/s?__biz=MzUyNTgyNjUzMw==&mid=2247541361&idx=1&sn=1d112e7d4f63a1561c7782937f756371&chksm=fa1a42fbcd6dcbedfd4ade1a7f98c986ae667244a2fc4c23e42fa9b4a6cd707756f1942a858e&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">2020 Panorama: License out of Chinese New Drugs .
Domestic pharmaceutical companies are also increasing their R&D expenditures, but there is still a huge gap in R&D investment compared with Japan.
In the future, we will continue to increase investment in high-quality R&D, and we must innovate in R&D in order to see more Chinese pharmaceutical companies among the top 50 pharmaceutical companies in the world .
weixin.
qq.
com/s?__biz=MzUyNTgyNjUzMw==&mid=2247541361&idx=1&sn=1d112e7d4f63a1561c7782937f756371&chksm=fa1a42fbcd6dcbedfd4ade1a7f98c986ae667244a2fc4c23e42fa9b4a6cd707756f1942a858e&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">2020 panoramic review: Chinese new drug license out 2020 panoramic review: Chinese new drug license out .
In the future, we will continue to increase investment in high-quality R&D, and we must innovate in R&D in order to see more Chinese pharmaceutical companies among the top 50 pharmaceutical companies in the world .
For pharmaceutical companies, the success of innovative drugs must come from continuous R&D investment.
According to our statistics, in the 2020 Global Pharmaceutical Top50, Japanese pharmaceutical companies account for 7 companies, ranking relatively high, of which Takeda ranks 10; China has 4 companies on the list, ranking relatively low, but the gap is gradually narrowing.
Only by driving innovation through R&D can innovation gain competitiveness beyond its peers.
For this reason, let's compare the R&D investment of Chinese and Japanese pharmaceutical companies.
According to our statistics, in the 2020 Global Pharmaceutical Top50, Japanese pharmaceutical companies account for 7 companies, ranking relatively high, of which Takeda ranks 10; China has 4 companies on the list, ranking relatively low, but the gap is gradually narrowing.
Only by driving innovation through R&D can innovation gain competitiveness beyond its peers.
For this reason, let's compare the R&D investment of Chinese and Japanese pharmaceutical companies.
544px;text-align:justify;text-indent:0em;background-color:#FFFFFF;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'>
544px;text-align:justify;text-indent:0em;background-color:#FFFFFF;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'>
544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;line-height:2em;">
R&D investment of Chinese pharmaceutical companies
5px;line-height:2em;">R&D investment of Chinese pharmaceutical companies
5px;line-height:2em;">R&D investment of Chinese pharmaceutical companies
R&D investment of Chinese pharmaceutical companies
544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;text-indent:0em;background-color:#FFFFFF;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'> Let's take A-share and Hong Kong-listed companies as examples.
Selecting all pharmaceutical companies listed in the two places, the R&D expenditure ranking of the top 10 in the first three quarters of 2020 is shown in the following chart, of which BeiGene has invested 6.
068 billion yuan in R&D, ranking first.
Hengrui Pharmaceutical's R&D investment of 3.
344 billion yuan ranked second, and CSPC's R&D investment of 2.
266 billion yuan ranked third.
The top 10 pharmaceutical companies invested a total of about 20.
35 billion yuan in R&D expenses in the first three quarters, with an average R&D investment of about 2.
03 billion yuan.
(In addition, in the Hong Kong stocks, CStone Pharmaceuticals, China Resources Pharmaceuticals, Hansen Pharmaceuticals, Simcere Pharmaceuticals and Fuhong Henlius have invested in R&D of RMB 300-500 million in the interim report, but the third quarter report was not disclosed, so the ranking was not made)Let's take A-share and Hong Kong-listed companies as examples.
Selecting all pharmaceutical companies listed in the two places, the R&D expenditure ranking of the top 10 in the first three quarters of 2020 is shown in the following chart, of which BeiGene has invested 6.
068 billion yuan in R&D, ranking first.
Hengrui Pharmaceutical's R&D investment of 3.
344 billion yuan ranked second, and CSPC's R&D investment of 2.
266 billion yuan ranked third.
The top 10 pharmaceutical companies invested a total of about 20.
35 billion yuan in R&D expenses in the first three quarters, with an average R&D investment of about 2.
03 billion yuan.
(Also the cornerstone of medicine in Hong Kong, China Resources medicine, pharmacy Hansen, Simcere and complex macros Hanlin and other R & D investment in the mid-year report 3-5 billion, but did not disclose the three quarterly, it did not rank) us to A Take the listed companies of Hong Kong stocks and Hong Kong stocks as examples.
Selecting all pharmaceutical companies listed in the two places, the R&D expenditure ranking of the top 10 in the first three quarters of 2020 is shown in the following chart, of which BeiGene has invested 6.
068 billion yuan in R&D, ranking first.
544px;text-indent:0em;background-color:#FFFFFF;text-align:center;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'> Data source: financial report; collated by Yaorong Circle
Data source: financial report; collated by Yaorong Circle544px;text-align:justify;text-indent:0em;background-color:#FFFFFF;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'>
544px;text-align:justify;text-indent:0em;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'> According to our statistics, in the first three quarters, nearly 20 domestic listed pharmaceutical companies have invested more than 500 million yuan in R&D, more than 30 have more than 300 million yuan, and nearly 100 have more than 100 million yuan.
544px;text-align:justify;text-indent:0em;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'>
544px;text-indent:0em;background-color:#FFFFFF;text-align:center;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'>
544px;text-indent:0em;background-color:#FFFFFF;text-align:center;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'> Data source: financial report; collated by Yaorong Circle
Data source: financial report; collated by Yaorong Circle544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;line-height:2em;">
R&D investment of Japanese pharmaceutical companies
5px;line-height:2em;">R&D investment of Japanese pharmaceutical companies
5px;line-height:2em;">R&D investment of Japanese pharmaceutical companies
R&D investment of Japanese pharmaceutical companies
544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;text-indent:0em;background-color:#FFFFFF;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'> The Japanese fiscal year runs from April 1, 2020 to March 31, 2021.
According to our ranking of the Top10 R&D investment in the first three quarters of the fiscal year, Takeda ranked first, with R&D investment of 3.
254 billion US dollars, which is approximately 21.
02 billion yuan (based on 1 US dollar = 6.
46 yuan).
As shown in the top 10 ranking of Japanese pharmaceutical companies' R&D investment:The Japanese fiscal year runs from April 1, 2020 to March 31, 2021.
According to our ranking of the Top10 R&D investment in the first three quarters of the fiscal year, Takeda ranked first, with R&D investment of 3.
254 billion US dollars, which is approximately 21.
02 billion yuan (based on 1 US dollar = 6.
46 yuan).
As shown in the top 10 ranking of Japanese pharmaceutical companies' R&D investment:
544px;text-align:justify;text-indent:0em;background-color:#FFFFFF;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'>
544px;text-indent:0em;background-color:#FFFFFF;text-align:center;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'>
544px;text-indent:0em;background-color:#FFFFFF;text-align:center;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'> Data source: financial report; collated by the pharmaceutical industry circle
Data source: financial report; collated by the pharmaceutical industry circle544px;text-align:justify;text-indent:0em;background-color:#FFFFFF;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'>
544px;text-align:justify;text-indent:0em;background-color:#FFFFFF;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'> Japan's top 10 pharmaceutical companies spent a total of US$11.
629 billion in research and development in the first three quarters, or about RMB 75.
12 billion.
The average R&D investment of each pharmaceutical company is about 7.
5 billion yuan.
(Among them: Chugai Pharmaceutical is a subsidiary of Roche Holdings)Japan's top 10 pharmaceutical companies spent a total of US$11.
629 billion in research and development in the first three quarters, or about RMB 75.
12 billion.
The average R&D investment of each pharmaceutical company is about 7.
5 billion yuan.
(Among them: Chugai Pharmaceutical is a subsidiary of Roche Holdings)
544px;text-align:justify;text-indent:0em;background-color:#FFFFFF;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'>
544px;text-indent:0em;background-color:#FFFFFF;text-align:center;line-height:2em;box-sizing:border-box ;'>
544px;text-indent:0em;background-color:#FFFFFF;text-align:center;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'> Data source: financial report; collated by the pharmaceutical industry circle
Data source: financial report; collated by the pharmaceutical industry circle544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;line-height:2em;">
Comparison of R&D investment between China and Japan
5px;line-height:2em;">Comparison of R&D investment between China and Japan
5px;line-height:2em;">Comparison of R&D investment between China and Japan
Comparison of R&D investment between China and Japan
544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;text-indent:0em;background-color:#FFFFFF;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'> From the foregoing, we can clearly see that there is a large gap in R&D investment between Chinese and Japanese listed pharmaceutical companies.
Top10 total R & D investment from the point of view, the first three quarters of Japan's total investment of about 75.
12 billion yuan, the average invested 7.
5 billion yuan; Chinese pharmaceutical companies listed Top10 first three quarters of total R & D expenses 203.
5 or so billion, the average R & D investment in 20 one hundred million yuan about.
The R&D investment of Chinese pharmaceutical companies is equivalent to about a quarter of that of Japanese pharmaceutical companies.
The R&D investment of Japan's top 10 pharmaceutical companies accounts for about 17% of revenue , and most of the R&D investment accounts for more than 15% of revenue .
Most of the R&D investment of Chinese pharmaceutical companies accounts for less than 10% of revenue .
From the foregoing, we can clearly see that there is a large gap in R&D investment between Chinese and Japanese listed pharmaceutical companies.
Top10 total R & D investment from the point of view, the first three quarters of Japan's total investment of about 75.
12 billion yuan, the average invested 7.
5 billion yuan; Chinese pharmaceutical companies listed Top10 first three quarters of total R & D expenses 203.
5 or so billion, the average R & D investment in 20 one hundred million yuan about.
The R&D investment of Chinese pharmaceutical companies is equivalent to about a quarter of that of Japanese pharmaceutical companies.
The R&D investment of Japan's top 10 pharmaceutical companies accounts for about 17% of revenue , and most of the R&D investment accounts for more than 15% of revenue .
Most of the R&D investment of Chinese pharmaceutical companies accounts for less than 10% of revenue .
The top 10 listed pharmaceutical companies in China spent about 20.
35 billion yuan in research and development in the first three quarters , with an average research and development investment of about 2 billion yuan.
The R&D investment of Chinese pharmaceutical companies is equivalent to about a quarter of that of Japanese pharmaceutical companies.
The R&D investment of Japan's top 10 pharmaceutical companies accounts for about 17% of revenue , and most of the R&D investment accounts for more than 15% of revenue .
Most of the R&D investment of Chinese pharmaceutical companies accounts for less than 10% of revenue .
544px;text-align:justify;text-indent:0em;background-color:#FFFFFF;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'>
544px;text-indent:0em;background-color:#FFFFFF;text-align:center;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'>
544px;text-indent:0em;background-color:#FFFFFF;text-align:center;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'> Data source: financial report; collated by the pharmaceutical industry circle
Data source: financial report; collated by the pharmaceutical industry circle544px;text-align:justify;text-indent:0em;background-color:#FFFFFF;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'>
544px;text-align:justify;text-indent:0em;background-color:#FFFFFF;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'> Comparing Hengrui Medicine, the benchmark of China's innovative drugs, with Takeda in Japan, Hengrui Medicine’s R&D investment as a percentage of revenue increased from 10% in 2015 to 17% in 2019, and the gap with Takeda is narrowing.
Hengrui Medicine’s revenue in the first three quarters of 2020 was 19.
4 billion yuan, an increase of 14.
56%, and its net profit was 4.
25 billion yuan, an increase of 14%; Takeda’s revenue in the first three quarters of 2020 was US$23 billion, a decrease of 3.
6%, and its net profit was US$1.
Comparing Hengrui Medicine, the benchmark of China's innovative drugs, with Takeda in Japan, Hengrui Medicine’s R&D investment as a percentage of revenue increased from 10% in 2015 to 17% in 2019, and the gap with Takeda is narrowing.
Hengrui is also accelerating its deployment in recent years.
544px;text-indent:0em;background-color:#FFFFFF;text-align:center;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'>
544px;text-indent:0em;background-color:#FFFFFF;text-align:center;break-inside:auto;break-before:auto;break-after:auto;line-height:2em;box-sizing:border-box ;'> Data source: financial report; collated by the pharmaceutical industry circle
Data source: financial report; collated by the pharmaceutical industry circle544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;line-height:2em;">
to sum up
5px;line-height:2em;">to sum up
5px;line-height:2em;">to sum up
to sum up
544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;text-indent:0em;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'> Innovation is the only way for pharmaceutical companies to go global, and the success of innovation largely depends on high investment in research and development.
In recent years, with the strong support of national policies and social capital, Chinese pharmaceutical companies have developed Chinese-style Big Pharma, Biopharma and Biotech companies, and have now emerged in the field of global innovation.
For details, please refer to: weixin.
qq.
com/s?__biz=MzUyNTgyNjUzMw==&mid=2247541361&idx=1&sn=1d112e7d4f63a1561c7782937f756371&chksm=fa1a42fbcd6dcbedfd4ade1a7f98c986ae667244a2fc4c23e42fa9b4a6cd707756f1942a858e&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">2020 Panorama: License out of Chinese New Drugs .
Domestic pharmaceutical companies are also increasing their R&D expenditures, but there is still a huge gap in R&D investment compared with Japan.
In the future, we will continue to increase investment in high-quality R&D, and we must innovate in R&D in order to see more Chinese pharmaceutical companies among the top 50 pharmaceutical companies in the world .
In recent years, with the strong support of national policies and social capital, Chinese pharmaceutical companies have developed Chinese-style Big Pharma, Biopharma and Biotech companies, and have now emerged in the field of global innovation.
For details, please refer to: weixin.
qq.
com/s?__biz=MzUyNTgyNjUzMw==&mid=2247541361&idx=1&sn=1d112e7d4f63a1561c7782937f756371&chksm=fa1a42fbcd6dcbedfd4ade1a7f98c986ae667244a2fc4c23e42fa9b4a6cd707756f1942a858e&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">2020 Panorama: License out of Chinese New Drugs .
Domestic pharmaceutical companies are also increasing their R&D expenditures, but there is still a huge gap in R&D investment compared with Japan.
In the future, we will continue to increase investment in high-quality R&D, and we must innovate in R&D in order to see more Chinese pharmaceutical companies among the top 50 pharmaceutical companies in the world .
weixin.
qq.
com/s?__biz=MzUyNTgyNjUzMw==&mid=2247541361&idx=1&sn=1d112e7d4f63a1561c7782937f756371&chksm=fa1a42fbcd6dcbedfd4ade1a7f98c986ae667244a2fc4c23e42fa9b4a6cd707756f1942a858e&scene=21#wechat_redirect" data-itemshowtype="0" tab="innerlink" data-linktype="2" hasload="1" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">2020 panoramic review: Chinese new drug license out 2020 panoramic review: Chinese new drug license out .
In the future, we will continue to increase investment in high-quality R&D, and we must innovate in R&D in order to see more Chinese pharmaceutical companies among the top 50 pharmaceutical companies in the world .
